Blog Posts by Anita Szajek

USP and Synthetic Therapeutic Peptides

USP and SyntheticTherapeutic Peptides

Anita Szajek, Ph.D., principal scientific liaison to USP’s Expert Panel on Therapeutic Peptides, examines therapeutic peptides, the transition from recombinant to synthetic manufacturing routes, and regulatory and quality-related questions.

Share

Will Bovine Heparin Be Reintroduced into the U.S. Market?

Bovine Heparin in the U.S.

For the first time in more than 20 years, U.S. regulators are considering the reintroduction of bovine (cow-derived) heparin into the U.S., helping to address concerns about potential shortages and adulteration issues associated with this widely-used drug. 

Share

Ensuring the Quality of Synthetic Peptides

The global pharmaceutical landscape continues to evolve

Today, peptides represent one of the fastest growing segments in the pharmaceutical market. Hence, being able to manufacture peptides that are consistent in makeup and quality is an important priority for manufacturers of this drug class. This article discusses how the global pharmaceutical landscape continues to transform and how quality standards will play a growing role in the manufacture of these drugs.

Share